HOWL Werewolf Therapeutics Inc

$HOWL End of Q1 2027. Because the ticker will seamlessly convert to AMBX upon closing in Q1 2027, looking at current analyst twelve-month projections for HOWL provides insight into expected upside: • Consensus Average Target: Analysts hold an average consensus price target ranging between $4.00 and $5.61 per share. • High/Low Spans: The most optimistic Wall Street projections peak at $7.00 to $7.35, while the lowest baseline targets sit at $1.00 to $3.00.

$HOWL decent sized buy at 2pm. Maybe we get to see an asset sale ahead of the merger vote afterall

$HOWL Accummulation has dried up supply. Very little can be done to short this. Soon this will 🚀

Earnings expected in October 30: $HOWL upgraded by Zacks, estimated EPS -0.32. $VRRM change of CFO, estimated EPS 0.26 ARBB 1st semester revenues UP 100%, 2nd semester and FY2025 results are expected $HKD flat for a long time, $OABI estimated EPS -0.13

$HOWL CVR = amount of shares held at merger date. This will keep you carried forward on Howl’s molecules WTX-124 (an IL-2 INDUKINE for solid tumors) and WTX-330 (an IL-12 INDUKINE), alongside multiple other preclinical and clinical programs. Soon positive gains well above current. Again, shares have dried up.

$HOWL I will be very surprised if they don't sell the CVR assets before the reverse merger. They are heavily incentivized to do so even at a lower price than they might get later. They don't even need a full cash payment. Even just partial would be a great boost. I'm sitting here contemplating the share price going up at least 70% before the reverse merger and then getting another double-digit pop post-merger. Second-largest position.